ATELERIX LIFE SCIENCES

Atelerix Life Sciences is developing ATLX-0199, an active thiol-based compound from our platform of novel drugs, reverses opioid-induced side effects such as OIRD... Overdose deaths from synthetic opioids (primarily fentanyl) have become a massive crisis, approaching 40,000 in 2019, and growing since COVID-19. Atelerix's novel approach to opioid-induced unmet medical needs could diminish the number of opioid-related deaths... ATLX-0199 targets novel molecular pathways, modulating signals downstream from activated opioid receptors. Concept validated by extensive NIH-supported research/data. Atelerix is developing ATLX-0199 and other compounds in its pipeline to treat the range of opioid-induced side effects; first focus is OIRD in the hospital surgical/ICU setting.

Also known as: Atelerix Life Sciences Inc.

Primary location: Charlottesville United States